Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance

Wu, ZX; Yang, YQ; Teng, QX; Wang, JQ; Lei, ZN; Wang, JQ; Lusvarghi, S; Ambudkar, SV; Yang, DH; Chen, ZS

Yang, DH; Chen, ZS (corresponding author), St Johns Univ, Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Queens, NY 11439 USA.

CANCERS, 2020; 12 (1):

Abstract

Tivantinib, also known as ARQ-197, is a potent non-ATP competitive selective c-Met inhibitor currently under phase 3 clinical trial evaluation for liv......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索